Calcific Aortic Valve Disease
7
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study
Impact of TAVI on the Gut Microbiota and Its Metabolites
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Exploration of Manidipine to Reverse Aortic Valve Calcification
Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
Serum and Cellular Biomarkers for Aortic Valve Stenosis